The role of CXCR3 in DSS-induced colitis

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Chami, Belal ^a   Yeung, Amanda W S ^b   Van Vreden, Caryn ^a   King, Nicholas J C ^a   Bao, Shisan ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; DEXTRAN SULFATE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR; CXCR3 PROTEIN, MOUSE; CYTOKINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CELL MIGRATION; CELLULAR IMMUNITY; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; FEMALE; HISTOPATHOLOGY; LYMPHOCYTIC INFILTRATION; MACROPHAGE MIGRATION; MOUSE; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; ANIMAL; CHEMICALLY INDUCED; GENETICS; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASE; INTESTINE MUCOSA; KNOCKOUT MOUSE; PATHOLOGY;

ANIMALS; COLITIS; CYTOKINES; DEXTRAN SULFATE; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MICE; MICE, KNOCKOUT; RECEPTORS, CXCR3;

EID: 84903788664     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101622     Document Type: Article

References (53)

1. Gunnarsson C, Chen J, Rizzo JA, Ladapo JA, Lofland JH (2012) Direct health care insurer and out-of-pocket expenditures of inflammatory bowel disease: evidence from a US national survey. Dig Dis Sci 57: 3080-3091.
2. Heaton PC, Tundia NL, Schmidt N, Wigle PR, Kelton CM (2012) National burden of pediatric hospitalizations for inflammatory bowel disease: results from the 2006 Kids' Inpatient Database. J Pediatr Gastroenterol Nutr 54: 477-485.
3. Lazebnik LB, Parfenov AI, Guseinzade MG, Kniazev OV, Efremov LI (2011) [Analysis of total cost of treatment of patients with inflammatory bowel diseases]. Eksp Klin Gastroenterol: 3-7.
4. Park KT, Bass D (2011) Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States: a review. Inflamm Bowel Dis 17: 1603-1609.
5. Friswell M, Campbell B, Rhodes J (2010) The role of bacteria in the pathogenesis of inflammatory bowel disease. Gut Liver 4: 295-306.
6. Johansson ME, Gustafsson JK, Sjoberg KE, Petersson J, Holm L, et al. (2010) Bacteria penetrate the inner mucus layer before inflammation in the dextran sulfate colitis model. PLoS One 5: e12238.
7. Araki Y, Sugihara H, Hattori T (2006) In vitro effects of dextran sulfate sodium on a Caco-2 cell line and plausible mechanisms for dextran sulfate sodium-induced colitis. Oncol Rep 16: 1357-1362.
8. Lee IA, Bae EA, Hyun YJ, Kim DH (2010) Dextran sulfate sodium and 2,4,6-trinitrobenzene sulfonic acid induce lipid peroxidation by the proliferation of intestinal gram-negative bacteria in mice. J Inflamm (Lond) 7: 7.
9. Yadav PK, Chen C, Liu Z (2011) Potential role of NK cells in the pathogenesis of inflammatory bowel disease. J Biomed Biotechnol 2011: 348530.
10. Hundorfean G, Neurath MF, Mudter J (2012) Functional relevance of T helper 17 (Th17) cells and the IL-17 cytokine family in inflammatory bowel disease. Inflamm Bowel Dis 18: 180-186.
11. Nanki T, Takada K, Komano Y, Morio T, Kanegane H, et al. (2009) Chemokine receptor expression and functional effects of chemokines on B cells: implication in the pathogenesis of rheumatoid arthritis. Arthritis Res Ther 11: R149.
12. Goldberg SH, van der Meer P, Hesselgesser J, Jaffer S, Kolson DL, et al. (2001) CXCR3 expression in human central nervous system diseases. Neuropathol Appl Neurobiol 27: 127-138. (Pubitemid 32591969)
13. Yoon KC, Park CS, You IC, Choi HJ, Lee KH, et al. (2010) Expression of CXCL9, -10, -11, and CXCR3 in the tear film and ocular surface of patients with dry eye syndrome. Invest Ophthalmol Vis Sci 51: 643-650.
14. Chen SC, de Groot M, Kinsley D, Laverty M, McClanahan T, et al. (2010) Expression of chemokine receptor CXCR3 by lymphocytes and plasmacytoid dendritic cells in human psoriatic lesions. Arch Dermatol Res 302: 113-123.
15. Cole KE, Strick CA, Paradis TJ, Ogborne KT, Loetscher M, et al. (1998) Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 187: 2009-2021. (Pubitemid 28285570)
16. Kim CH, Rott L, Kunkel EJ, Genovese MC, Andrew DP, et al. (2001) Rules of chemokine receptor association with T cell polarization in vivo. J Clin Invest 108: 1331-1339. (Pubitemid 33107761)
17. Xie JH, Nomura N, Lu M, Chen SL, Koch GE, et al. (2003) Antibody-mediated blockade of the CXCR3 chemokine receptor results in diminished recruitment of T helper 1 cells into sites of inflammation. J Leukoc Biol 73: 771-780. (Pubitemid 38040456)
18. Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, et al. (2000) International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 52: 145-176. (Pubitemid 30127598)
19. Qin S, Rottman JB, Myers P, Kassam N, Weinblatt M, et al. (1998) The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 101: 746-754. (Pubitemid 28096070)
20. Thomas SY, Hou R, Boyson JE, Means TK, Hess C, et al. (2003) CD1d-restricted NKT cells express a chemokine receptor profile indicative of Th1-type inflammatory homing cells. J Immunol 171: 2571-2580. (Pubitemid 37025568)
21. Hartl D, Krauss-Etschmann S, Koller B, Hordijk PL, Kuijpers TW, et al. (2008) Infiltrated neutrophils acquire novel chemokine receptor expression and chemokine responsiveness in chronic inflammatory lung diseases. J Immunol 181: 8053-8067.
22. Schroepf S, Kappler R, Brand S, Prell C, Lohse P, et al. (2010) Strong overexpression of CXCR3 axis components in childhood inflammatory bowel disease. Inflamm Bowel Dis 16: 1882-1890.
23. Yuan YH, ten Hove T, The FO, Slors JF, van Deventer SJ, et al. (2001) Chemokine receptor CXCR3 expression in inflammatory bowel disease. Inflamm Bowel Dis 7: 281-286. (Pubitemid 33062092)
24. Papadakis KA (2004) Chemokines in inflammatory bowel disease. Curr Allergy Asthma Rep 4: 83-89.
25. Singh UP, Venkataraman C, Singh R, Lillard JW Jr (2007) CXCR3 axis: role in inflammatory bowel disease and its therapeutic implication. Endocr Metab Immune Disord Drug Targets 7: 111-123. (Pubitemid 46969859)
26. Nishimura M, Kuboi Y, Muramoto K, Kawano T, Imai T (2009) Chemokines as novel therapeutic targets for inflammatory bowel disease. Ann N Y Acad Sci 1173: 350-356.
27. Tokuyama H, Ueha S, Kurachi M, Matsushima K, Moriyasu F, et al. (2005) The simultaneous blockade of chemokine receptors CCR2, CCR5 and CXCR3 by a non-peptide chemokine receptor antagonist protects mice from dextran sodium sulfate-mediated colitis. Int Immunol 17: 1023-1034. (Pubitemid 41158385)
28. Xu Y, Hunt NH, Bao S (2008) The role of granulocyte macrophage-colony- stimulating factor in acute intestinal inflammation. Cell Res 18: 1220-1229.
29. Danese S, Papa A, Scaldaferri F, Graziani C, Bonizzi M, et al. (2006) A novel pathogenic role for microvasculature in inflammatory bowel disease. Eur Rev Med Pharmacol Sci 10: 3-5.
30. Rose WA 2nd, Sakamoto K, Leifer CA (2012) Multifunctional role of dextran sulfate sodium for in vivo modeling of intestinal diseases. BMC Immunol 13: 41.
31. Lee PY, Wang JX, Parisini E, Dascher CC, Nigrovic PA (2013) Ly6 family proteins in neutrophil biology. J Leukoc Biol 94: 585-594.
32. Kim HS, Chung DH (2013) IL-9-producing invariant NKT cells protect against DSS-induced colitis in an IL-4-dependent manner. Mucosal Immunol 6: 347-357.
33. Yan F, Wang L, Shi Y, Cao H, Liu L, et al. (2012) Berberine promotes recovery of colitis and inhibits inflammatory responses in colonic macrophages and epithelial cells in DSS-treated mice. Am J Physiol Gastrointest Liver Physiol 302: G504-514.
34. Martinez Gomez JM, Chen L, Schwarz H, Karrasch T (2014) Correction: CD137 Facilitates the Resolution of Acute DSS-Induced Colonic Inflammation in Mice. PLoS One 9.
35. Pedersen J, Coskun M, Soendergaard C, Salem M, Nielsen OH (2014) Inflammatory pathways of importance for management of inflammatory bowel disease. World J Gastroenterol 20: 64-77.
36. Lacotte S, Brun S, Muller S, Dumortier H (2009) CXCR3, inflammation, and autoimmune diseases. Ann N Y Acad Sci 1173: 310-317.
37. Lalor SJ, Segal BM (2013) Th1-mediated experimental autoimmune encephalomyelitis is CXCR3 independent. Eur J Immunol 43: 2866-2874.
38. Groom JR, Luster AD (2011) CXCR3 in T cell function. Exp Cell Res 317: 620-631.
39. Choi J, Ziga ED, Ritchey J, Collins L, Prior JL, et al. (2012) IFNgammaR signaling mediates alloreactive T-cell trafficking and GVHD. Blood 120: 4093-4103.
40. Cohen SB, Maurer KJ, Egan CE, Oghumu S, Satoskar AR, et al. (2013) CXCR3-dependent CD4(+) T cells are required to activate inflammatory monocytes for defense against intestinal infection. PLoS Pathog 9: e1003706.
41. Xu Y, Hunt NH, Bao S (2008) The effect of restraint stress on experimental colitis is IFN-gamma independent. J Neuroimmunol 200: 53-61.
42. Boxer LA (2008) Role of neutrophils in genetic disorders of phagocyte function leading to IBD. J Pediatr Gastroenterol Nutr 46 Suppl 1: E17.
43. Mohan K, Issekutz TB (2007) Blockade of chemokine receptor CXCR3 inhibits T cell recruitment to inflamed joints and decreases the severity of adjuvant arthritis. J Immunol 179: 8463-8469.
44. Ichikawa A, Kuba K, Morita M, Chida S, Tezuka H, et al. (2013) CXCL10-CXCR3 enhances the development of neutrophil-mediated fulminant lung injury of viral and nonviral origin. Am J Respir Crit Care Med 187: 65-77.
45. Steinbeck MJ, Roth JA, Kaeberle ML (1986) Activation of bovine neutrophils by recombinant interferon-gamma. Cell Immunol 98: 137-144. (Pubitemid 16112021)
46. Fang Y, Shen J, Yao M, Beagley KW, Hambly BD, et al. (2010) Granulocyte-macrophage colony-stimulating factor enhances wound healing in diabetes via upregulation of proinflammatory cytokines. Br J Dermatol 162: 478-486.
47. Raza A, Yousaf W, Giannella R, Shata MT (2012) Th17 cells: interactions with predisposing factors in the immunopathogenesis of inflammatory bowel disease. Expert Rev Clin Immunol 8: 161-168.
48. Strober W, Fuss IJ (2011) Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 140: 1756-1767.
49. Groom JR, Richmond J, Murooka TT, Sorensen EW, Sung JH, et al. (2012) CXCR3 chemokine receptor-ligand interactions in the lymph node optimize CD4+ T helper 1 cell differentiation. Immunity 37: 1091-1103.
50. Barbi J, Oghumu S, Lezama-Davila CM, Satoskar AR (2007) IFN-gamma and STAT1 are required for efficient induction of CXC chemokine receptor 3 (CXCR3) on CD4+ but not CD8+ T cells. Blood 110: 2215-2216. (Pubitemid 47443944)
51. Yellin M, Paliienko I, Balanescu A, Ter-Vartanian S, Tseluyko V, et al. (2012) A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 64: 1730-1739.
52. Bao S, Carr ED, Xu YH, Hunt NH (2011) Gp91(phox) contributes to the development of experimental inflammatory bowel disease. Immunol Cell Biol 89: 853-860.
53. Park CM, Reid PE, Walker DC, MacPherson BR (1987) A simple, practical 'swiss roll' method of preparing tissues for paraffin or methacrylate embedding. J Microsc 145: 115-120. (Pubitemid 17025003)